Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease after acute myocardial infarction

Chen et al. evaluated the cardiovascular safety and efficacy of sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, in 1,025 type 2 diabetic patients with chronic kidney disease (CKD) after acute myocardial infarction (AMI) [1]. The authors set the primary outcomes as myocardial infarction, ischemic stroke or cardiovascular death, and they conducted a one-year follow-up with use of Cox proportional hazard models. Although, the use of sitagliptin was not associated with an increased risk of cardiovascular death, ischemic stroke or hospitalization for heart failure, hazard ratios (95% confidence intervals) of sitagliptin use for recurrent AMI and percutaneous coronary revascularization were 1.73 (1.15-2.58) and 1.43 (1.04-1.95), respectively.
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Correspondence Source Type: research